Response of canine cutaneous epitheliotropic lymphoma to lomustine (CCNU): A retrospective study of 46 cases (1999-2004)

Rebecca E. Risbon, L. P. De Lorimier, Katherine A Skorupski, K. E. Burgess, P. J. Bergman, J. Carreras, K. Hahn, A. LeBlanc, M. Turek, J. Impellizeri, R. Fred, J. W. Wojcieszyn, K. Drobatz, C. A. Clifford

Research output: Contribution to journalArticle

58 Scopus citations

Abstract

Background: Epitheliotropic lymphoma (ELSA) is an uncommon cutaneous canine malignancy of T lymphocytes. A consensus regarding the therapeutic standard of care is lacking, warranting evaluation of chemotherapeutic agents traditionally employed against canine nodal lymphoma in the treatment of ELSA. Hypothesis: The purpose of this retrospective, multi-institutional study was to evaluate the efficacy of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) in the treatment of ELSA. Animals: Forty-six dogs with adequate follow-up and treatment response information. Methods: All cases were diagnosed histopathologically. Immunohistochemisty (CD3, CD79a) was performed on 42/46 samples. Results: Presenting skin lesions included generalized scales (25/46), plaques or nodules (22/46), mucocutaneous lesions (14/ 46), and corneal involvement (1/46). Lymph node involvement and Sézary syndrome were documented in 7 and 2 dogs, respectively. The median number of CCNU treatments was 4 (range, 1-11), with a median starting dose of 60 mg/m2 (range, 30-95). Of the 46 dogs, 15 achieved complete remission, 23 achieved partial remission, 5 had stable disease, and 3 had progressive disease, for an overall response rate of 83%. The median number of treatments to achieve a response was 1 (range, 1-6). The overall median duration of response was 94 days (range, 22-282). Sixteen dose reductions were required because of neutropenia (10/46), thrombocytopenia (1/46), anemia (1/46), increased liver enzyme activity (3/46), or unspecified reasons (1/46). Conclusions and Clinical Implications: Given the high response rate and well tolerated protocol, prospective studies are warranted to investigate the utility of CCNU alone or in multi-agent protocols for the treatment of ELSA.

Original languageEnglish (US)
Pages (from-to)1389-1397
Number of pages9
JournalJournal of Veterinary Internal Medicine
Volume20
Issue number6
DOIs
StatePublished - Nov 2006
Externally publishedYes

Keywords

  • Alkylator
  • Chemotherapy
  • Epitheliotropic lymphoma
  • Mycosis fungoides
  • Nitrosourea
  • Skin

ASJC Scopus subject areas

  • veterinary(all)

Fingerprint Dive into the research topics of 'Response of canine cutaneous epitheliotropic lymphoma to lomustine (CCNU): A retrospective study of 46 cases (1999-2004)'. Together they form a unique fingerprint.

  • Cite this

    Risbon, R. E., De Lorimier, L. P., Skorupski, K. A., Burgess, K. E., Bergman, P. J., Carreras, J., Hahn, K., LeBlanc, A., Turek, M., Impellizeri, J., Fred, R., Wojcieszyn, J. W., Drobatz, K., & Clifford, C. A. (2006). Response of canine cutaneous epitheliotropic lymphoma to lomustine (CCNU): A retrospective study of 46 cases (1999-2004). Journal of Veterinary Internal Medicine, 20(6), 1389-1397. https://doi.org/10.1892/0891-6640(2006)20[1389:ROCCEL]2.0.CO;2